Immunotherapy
ABBV-514 + Budigalimab for Lung & Head and Neck Cancers
Recruiting1 awardPhase 1
Huntersville, North Carolina
This trial is testing two experimental drugs, ABBV-514 and Budigalimab, on adults with specific types of cancer. The goal is to find out if these drugs can help treat lung and head/neck cancers by monitoring their effects and side effects.
PI3K Inhibitor
Tipifarnib + Alpelisib for Head and Neck Cancer
Recruiting1 awardPhase 1 & 2
Orlando, Florida
This trial tests a combination of two drugs, tipifarnib and alpelisib, in patients with advanced head and neck cancer that have specific genetic changes. The drugs aim to stop cancer growth by blocking essential enzymes. Tipifarnib is a farnesyl transferase inhibitor that has shown clinical activity in head and neck squamous cell carcinoma, particularly in tumors with HRAS mutations.
Behavioural Intervention
MIT-001 for Oral Mucositis Prevention in Head and Neck Cancer Patients
Recruiting0 awardsPhase 2
Gilbert, Arizona
This trial tests MIT-001, a drug that reduces harmful molecules to prevent inflammation, in patients with advanced head and neck cancer undergoing chemoradiotherapy. The goal is to prevent painful mouth sores by protecting cells and blocking inflammation pathways.
PARP Inhibitor
Niraparib + Dostarlimab for Head and Neck Cancer
Recruiting2 awardsPhase 2
Cincinnati, Ohio
This trial tests a combination of two drugs, dostarlimab and niraparib, in patients with head and neck cancer that has come back or spread. Dostarlimab helps the immune system attack cancer, while niraparib prevents cancer cells from repairing themselves. Niraparib is an oral drug approved for maintenance treatment in ovarian, fallopian tube, or primary peritoneal cancer.
Popular Filters
Trials for Head And Neck Squamous Cell Carcinoma Patients
Monoclonal Antibodies
Pembrolizumab +/− Lenvatinib for Head and Neck Cancer
Recruiting1 awardPhase 3
Fresno, California
This trial is studying whether giving pembrolizumab with or without lenvatinib to people with cancer of the head and neck who have PD-L1 selection is better than giving pembrolizumab with placebo.
Monoclonal Antibodies
Ibrutinib + Nivolumab/Cetuximab for Head and Neck Cancer
Recruiting1 awardPhase 2
La Jolla, California
This trial is testing whether ibrutinib, in combination with either nivolumab or cetuximab, is effective in treating recurrent and/or metastatic head and neck squamous cell carcinoma.
Trials for Head And Neck Cancers Patients
Monoclonal Antibodies
Ibrutinib + Nivolumab/Cetuximab for Head and Neck Cancer
Recruiting1 awardPhase 2
La Jolla, California
This trial is testing whether ibrutinib, in combination with either nivolumab or cetuximab, is effective in treating recurrent and/or metastatic head and neck squamous cell carcinoma.
Chemotherapy
Duvelisib + Docetaxel for Head and Neck Cancer
Recruiting1 awardPhase 2
Boston, Massachusetts
This trial is testing a combination of a pill (Duvelisib) and an IV drug (Docetaxel) for patients with head and neck cancer that has come back or spread. These patients did not respond to initial treatments. Duvelisib stops cancer cells from growing, and Docetaxel kills them by preventing cell division.
Trials for P16 Positive Patients
Monoclonal Antibodies
Ibrutinib + Nivolumab/Cetuximab for Head and Neck Cancer
Recruiting1 awardPhase 2
La Jolla, California
This trial is testing whether ibrutinib, in combination with either nivolumab or cetuximab, is effective in treating recurrent and/or metastatic head and neck squamous cell carcinoma.
Chemotherapy
Pembrolizumab + Olaparib for Head and Neck Cancer
Recruiting1 awardPhase 2
Chapel Hill, North Carolina
This trial will test whether using pembrolizumab and olaparib together before and after chemoradiation therapy is more effective in treating locally advanced head and neck squamous cell carcinoma than chemoradiation therapy alone.
Trials for PD-L1 Positive Patients
Chemotherapy
Duvelisib + Docetaxel for Head and Neck Cancer
Recruiting1 awardPhase 2
Boston, Massachusetts
This trial is testing a combination of a pill (Duvelisib) and an IV drug (Docetaxel) for patients with head and neck cancer that has come back or spread. These patients did not respond to initial treatments. Duvelisib stops cancer cells from growing, and Docetaxel kills them by preventing cell division.
Antisense Oligonucleotide
Danvatirsen + Pembrolizumab for Head and Neck Cancer
Recruiting1 awardPhase 2
Merriam, Kansas
This trial is testing danvatirsen with pembrolizumab in patients with head and neck cancer that has returned or spread. Danvatirsen aims to stop cancer growth, and pembrolizumab helps the immune system attack the cancer.
Trials With No Placebo
Monoclonal Antibodies
Ibrutinib + Nivolumab/Cetuximab for Head and Neck Cancer
Recruiting1 awardPhase 2
La Jolla, California
This trial is testing whether ibrutinib, in combination with either nivolumab or cetuximab, is effective in treating recurrent and/or metastatic head and neck squamous cell carcinoma.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.